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The tumor necrosis factor (TNF)-related apoptosis indu-
cing ligand (TRAIL/Apo-2L) is a member of the TNF
superfamily that trigger and activate 2 death receptors,
DR4 and DR5, and 2 decoy receptors, DcR1 and DcR2.
Several studies demonstrated that TRAIL in monother-
apy can induces cancer cell death cells, but few have
been done in leukemias in combination with conven-
tional drugs. The aim of this work is to analyse the
potential synergist effect of a recombinant TRAIL
(rhTRAIL) in myeloid leukemias.
For this, 2 myeloid leukemia cell lines, HL-60 (pro-
myelocitic leukemia) and K-562 (Chronic Myeloid Leu-
kemia) were treated with different concentrations of
rhTRAIL as single agent and in combination with
ATRA (all-transretinoic acid) and imatinib, respectively.
The viability was measure using the trypan blue test and
cell death by flow cytometry (FC) and Optical Micro-
scopy. TRAIL and TRAIL-Rs were evaluated by FC.
Our results show that rhTRAIL induced a decrease in
cell viability inducing cell death, in a time, dose and cell
type dependent manner. We observe an IC50 in HL-60
treated for 48h of 250 ng/mL, although in K562 cells,
rhTRAIL wasn’t able to induce a significant effect. How-
ever, when we previously treated the cells with ATRA
or IMATINIB a synergistic effect is observed, mainly in
HL60 cells. These results may be correlated with the dif-
ferential TRAIL receptors expression, namely the pre-
sence of the anti-apoptotic TRAIL receptors, in K562
cells. On the other hand, the higher percentage of pro-
apoptotic TRAIL receptors may be related with the ther-
apeutic efficacy of rhTRAIL in HL-60 cells. Our study
suggests that rhTRAIL can be use as a new therapeutic
aproach in APL, as single agent. However, it can
potentiate the cytotoxic effect of conventional drugs.
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